Mineralys Therapeutics (MLYS) said late Tuesday it priced an underwritten public offering of nearly 13 million shares at $13.50 each to raise an expected $175 million in gross proceeds.
The company granted underwriters a 30-day option to purchase about 1.9 million additional shares.
The offering is expected to close on Thursday, with the proceeds to fund clinical development of lorundrostat, including research, manufacturing and pre-commercialization activities, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。